PECENED 144-906 Docket No.

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Myles C. Cabot et al.

Assignee:

John Wayne Cancer

Institute

Filing Date:

November 12, 1999

Examiner:

J. Zara

Serial No.:

09/439,293

Group Art Unit: 1635

Title:

Methods of Reversing Drug Resistance in Cancer Cells

**Assistant Commissioner for Patents** Washington, D.C. 20231

#### INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed on the attached Form PTO-1449 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application.

## I. Timing of the Information Disclosure Statement:

This Information Disclosure Statement is filed:

After the first Office Action and more than three months after the application's  $\bowtie$ filing date; or PCT national stage date of entry filing but, as far as is known to the undersigned, prior to the mailing date of either a final rejection or a notice of allowance, whichever occurs first, and the Commissioner is hereby authorized to charge Deposit Account No. 50-1189 for the fee (\$240) set forth in 37 C.F.R. § 1.17(p) and any additional required fees.

### II. Copies of the Cited Items:

Copies of all of the items listed on the attached Form PTO-1449 are enclosed.  $\boxtimes$ 

# III. Concise Explanation of Relevance:

A concise explanation of relevance of the items listed on Form PTO-1449 is not given.

#### IV. Conclusion:

Citation of the above documents shall not be construed as:

- 1. an admission that the documents are necessarily prior art with respect to the instant invention;
- 2. a representation that a search has been made, other than as described above; or
- an admission that the information cited herein is, or is considered to be, material to patentability as defined in § 1.56(b).

It is respectfully requested that the Examiner indicate consideration of the cited references by returning a copy of the attached form PTO 1449 with initials or other appropriate marks.

The Commissioner is hereby authorized to charge Deposit Account No. <u>50-1189</u> Docket No.: <u>21144-706</u> for any additional fees required in connection with the filing of this Information Disclosure Statement.

DATE: January 8, 2001

Respectfully submitted,

By:

Carol M. Gruppi

Registration No.: 37,34

McCutchen, Doyle, Brown & Enersen, LLP

Three Embarcadero Center San Francisco, California 94111

Telephone: (650) 849-4400 Telefax: (650) 849-4800